Diabetes, but not pre-diabetes, is associated with shorter time to second-line therapy and worse outcomes in patients with multiple myeloma

References

• Szabo AG, Iversen KF, Möller S, et al. The clinical course of multiple myeloma in the era of novel agents: a retrospective, single-center, real-world study. Clin Hematol Int. 2019;1(4):220–228.
   PubMedGoogle Scholar
• Nandakumar B, Binder M, Dispenzieri A, et al. Continued improvement in survival in multiple myeloma (MM) including high-risk patients. In: American Society of Clinical Oncology Annual Meeting; Chicago, Illinois; 2019.
   Google Scholar
• Usmani SZ, Hoering A, Cavo M, et al. Clinical predictors of long-term survival in newly diagnosed transplant eligible multiple myeloma – an IMWG Research Project. Blood Cancer J. 2018;8(12):123.
   PubMed Web of Science ®Google Scholar
• Avet-Loiseau H, Soulier J, Fermand J-P, et al. Impact of high-risk cytogenetics and prior therapy on outcomes in patients with advanced relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone. Leukemia. 2010;24(3):623–628.
   PubMed Web of Science ®Google Scholar
• Palumbo A, Avet-Loiseau H, Oliva S, et al. Revised international staging system for multiple myeloma: a report from International Myeloma Working Group. J Clin Oncol. 2015;33(26):2863–2869.
   PubMed Web of Science ®Google Scholar
• Chou Y-S, Yang C-F, Chen H-S, et al. Pre-existing diabetes mellitus in patients with multiple myeloma. Eur J Haematol. 2012;89(4):320–327.
   PubMed Web of Science ®Google Scholar
• Wu W, Merriman K, Nabaah A, et al. The association of diabetes and anti-diabetic medications with clinical outcomes in multiple myeloma. Br J Cancer. 2014;111(3):628–636.
   PubMed Web of Science ®Google Scholar
• Ríos-Tamayo R, Sánchez MJ, Puerta JM, et al. Trends in survival of multiple myeloma: a thirty-year population-based study in a single institution. Cancer Epidemiol. 2015;39(5):693–699.
   PubMed Web of Science ®Google Scholar
• Ríos-Tamayo R, Sáinz J, Martínez-López J, et al. Early mortality in multiple myeloma: the time-dependent impact of comorbidity: a population-based study in 621 real-life patients. Am J Hematol. 2016;91(7):700–704.
   PubMed Web of Science ®Google Scholar
• Hsiao L-T, Chiou T-J, Hong Y-C, et al. Comorbid diabetes does not impact the survival of patients with multiple myeloma. Blood. 2010;116(21):5003–5003.
   Google Scholar
• Ríos Tamayo R, Sainz J, Jiménez-Moleón J, et al. Obesity and multiple myeloma: what do the data tell us? J Leuk. 2014;2:2.
   Google Scholar
• Rajkumar SV, Dimopoulos MA, Palumbo A, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15(12):e538–e548.
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. Classification and diagnosis of diabetes. Diabetes Care. 2015;38(Suppl.):S8–S16.
   Web of Science ®Google Scholar
• Chodick G, Heymann AD, Shalev V, et al. The epidemiology of diabetes in a large Israeli HMO. Eur J Epidemiol. 2002;18(12):1143–1146.
   Web of Science ®Google Scholar
• Coresh J, Turin TC, Matsushita K, et al. Decline in estimated glomerular filtration rate and subsequent risk of end-stage renal disease and mortality. JAMA. 2014;311(24):2518–2531.
   PubMed Web of Science ®Google Scholar
• Body Mass Index – BMI [Internet]; 2020; [cited 2020 Nov 15]. Available from: https://www.euro.who.int/en/health-topics/disease-prevention/nutrition/a-healthy-lifestyle/body-mass-index-bmi
   Google Scholar
• Israel Central Bureau of Statistics. 1995 census of population and housing. Jerusalem; 1998. https://www.cbs.gov.il/en/publications/Pages/1998/Census-of-Population-and-Housing-1995-tatistical-Abstract-of-Israel-1998-No49.aspx
   Google Scholar
• Schjesvold FH, Jenna A, Sõnajalg J, et al. Predictors of overall survival for multiple myeloma patients depending on transplant status according to a retrospective, non-interventional study in Norway. Blood. 2018;132(Suppl. 1):5759.
   Google Scholar
• Castillo JJ, Mull N, Reagan JL, et al. Increased incidence of non-Hodgkin lymphoma, leukemia, and myeloma in patients with diabetes mellitus type 2: a meta-analysis of observational studies. Blood. 2012;119(21):4845–4850.
   PubMed Web of Science ®Google Scholar
• Cowie CC, Eberhardt MS. Sociodemographic characteristics of persons with diabetes. In: Harris MI, Cowie CC, Stern MP, Boyko EJ, Reiber GE, Bennett PH editor. Diabetes in America; Bethesda MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases.1995. p. 85–100.
   Google Scholar
• Ríos R, Lupiañez CB, Campa D, et al. Type 2 diabetes-related variants influence the risk of developing multiple myeloma: results from the IMMEnSE consortium. Endocr Relat Cancer. 2015;22(4):545–559.
   PubMed Web of Science ®Google Scholar
• Sprynski AC, Hose D, Kassambara A, et al. Insulin is a potent myeloma cell growth factor through insulin/IGF-1 hybrid receptor activation. Leukemia. 2010;24(11):1940–1950.
   PubMed Web of Science ®Google Scholar
• Garg SK, Maurer H, Reed K, et al. Diabetes and cancer: two diseases with obesity as a common risk factor. Diabetes Obes Metab. 2014;16(2):97–110.
   PubMed Web of Science ®Google Scholar
• Termini JS. TOXI 4: hyperglycemia induced DNA damage and inhibition of DNA repair: potential mechanistic link between diabetes and increased cancer risk. In: American Chemical Society National Meeting; San Diego, CA; 2019.
   Google Scholar
• Markus E, Trestman S, Cohen Y, et al. Components of metabolic syndrome in patients with multiple myeloma and smoldering multiple myeloma. BMC Cancer. 2020;20(1):489.
   PubMed Web of Science ®Google Scholar
• Rios-Tamayo R, Perez JS, Jimenez-Moleon JJ, et al. Type 2 diabetes and multiple myeloma : the latest insights. J Leuk. 2014;2(3):2–3.
   Google Scholar
• Weil C, Gelerstein S, Sharman Moser S, et al. Real-world epidemiology, treatment patterns and survival of multiple myeloma patients in a large nationwide health plan. Leuk Res. 2019;85:106219.
   PubMed Web of Science ®Google Scholar
• Yu W, Cao D, Zhou H, et al. PGC-1α is responsible for survival of multiple myeloma cells under hyperglycemia and chemotherapy. Oncol Rep. 2015;33(4):2086–2092.
   PubMed Web of Science ®Google Scholar
• Bieghs L, Johnsen HE, Maes K, et al. The insulin-like growth factor system in multiple myeloma: diagnostic and therapeutic potential. Oncotarget. 2016;7(30):48732–48752.
   PubMedGoogle Scholar
• Gerards MC, van der Velden DL, Baars JW, et al. Impact of hyperglycemia on the efficacy of chemotherapy—a systematic review of preclinical studies. Crit Rev Oncol Hematol. 2017;113:235–241.
   PubMed Web of Science ®Google Scholar